Literature DB >> 10077649

Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia.

K Ihara1, E Ishii, M Eguchi, H Takada, A Suminoe, R A Good, T Hara.   

Abstract

Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare disorder expressed in infancy and characterized by isolated thrombocytopenia and megakaryocytopenia with no physical anomalies. Our previous hematological analysis indicated similarities between human CAMT and murine c-mpl (thrombopoietin receptor) deficiency. Because the c-mpl gene was considered as one of the candidate genes for this disorder, we analyzed the genomic sequence of the c-mpl gene of a 10-year-old Japanese girl with CAMT. We detected two heterozygous point mutations: a C-to-T transition at the cDNA nucleotide position 556 (Q186X) in exon 4 and a single nucleotide deletion of thymine at position 1,499 (1,499 delT) in exon 10. Both mutations were predicted to result in a prematurely terminated c-Mpl protein, which, if translated, lacks all intracellular domains essential for signal transduction. Each of the mutations was segregated from the patient's parents. Accordingly, the patient was a compound heterozygote for two mutations of the c-mpl gene, each derived from one of the parents. The present study suggests that at least a certain type of CAMT is caused by the c-mpl mutation, which disrupts the function of thrombopoietin receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077649      PMCID: PMC15907          DOI: 10.1073/pnas.96.6.3132

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

Review 1.  Messenger RNA degradation in eukaryotes.

Authors:  A B Sachs
Journal:  Cell       Date:  1993-08-13       Impact factor: 41.582

2.  Congenital hypoplastic thrombocytopenia and cerebral malformations in two brothers.

Authors:  H M Hoyeraal; J Lamvik; P J Moe
Journal:  Acta Paediatr Scand       Date:  1970-03

3.  Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.

Authors:  F J de Sauvage; P E Hass; S D Spencer; B E Malloy; A L Gurney; S A Spencer; W C Darbonne; W J Henzel; S C Wong; W J Kuang
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

Review 4.  Thrombocytopenia with absent radii. A review of 100 cases.

Authors:  V A Hedberg; J M Lipton
Journal:  Am J Pediatr Hematol Oncol       Date:  1988

5.  Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily.

Authors:  I Vigon; J P Mornon; L Cocault; M T Mitjavila; P Tambourin; S Gisselbrecht; M Souyri
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

6.  Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo.

Authors:  S Lok; K Kaushansky; R D Holly; J L Kuijper; C E Lofton-Day; P J Oort; F J Grant; M D Heipel; S K Burkhead; J M Kramer
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

7.  Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development.

Authors:  K Kaushansky; V C Broudy; N Lin; M J Jorgensen; J McCarty; N Fox; D Zucker-Franklin; C Lofton-Day
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

8.  Thrombocytopenia in c-mpl-deficient mice.

Authors:  A L Gurney; K Carver-Moore; F J de Sauvage; M W Moore
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

9.  Congenital amegakaryocytic thrombocytopenia: an intrinsic hematopoietic stem cell defect.

Authors:  M H Freedman; Z Estrov
Journal:  Am J Pediatr Hematol Oncol       Date:  1990

10.  Thrombopoietin receptor expression in human cancer cell lines and primary tissues.

Authors:  L Columbyova; M Loda; D T Scadden
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

View more
  65 in total

1.  Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ.

Authors:  Luigi J Alvarado; Heather D Huntsman; Hai Cheng; Danielle M Townsley; Thomas Winkler; Xingmin Feng; Cynthia E Dunbar; Neal S Young; Andre Larochelle
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

2.  Modifier screens in the mouse: time to move forward with reverse genetics.

Authors:  David J Curtis
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

3.  Inherited bone marrow failure syndromes.

Authors:  Inderjeet Dokal; Tom Vulliamy
Journal:  Haematologica       Date:  2010-08       Impact factor: 9.941

Review 4.  Regulating billions of blood platelets: glycans and beyond.

Authors:  Renata Grozovsky; Silvia Giannini; Hervé Falet; Karin M Hoffmeister
Journal:  Blood       Date:  2015-09-01       Impact factor: 22.113

5.  Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.

Authors:  Kellie R Machlus; Stephen K Wu; Prakrith Vijey; Thomas S Soussou; Zhi-Jian Liu; Eran Shacham; T J Unger; Trinayan Kashyap; Boris Klebanov; Martha Sola-Visner; Marsha Crochiere; Joseph E Italiano; Yosef Landesman
Journal:  Blood       Date:  2017-06-19       Impact factor: 22.113

Review 6.  Megakaryocyte biology and related disorders.

Authors:  Liyan Pang; Mitchell J Weiss; Mortimer Poncz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 7.  The molecular mechanisms that control thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

8.  Developmental Stage-Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice.

Authors:  Viola Lorenz; Haley Ramsey; Zhi-Jian Liu; Joseph Italiano; Karin Hoffmeister; Sihem Bihorel; Donald Mager; Zhongbo Hu; William B Slayton; Benjamin T Kile; Martha Sola-Visner; Francisca Ferrer-Marin
Journal:  Thromb Haemost       Date:  2017-12-06       Impact factor: 5.249

Review 9.  Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.

Authors:  Roberto Stasi; Maria L Evangelista; Sergio Amadori
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling.

Authors:  Marina R Carpinelli; Douglas J Hilton; Donald Metcalf; Jennifer L Antonchuk; Craig D Hyland; Sandra L Mifsud; Ladina Di Rago; Adrienne A Hilton; Tracy A Willson; Andrew W Roberts; Robert G Ramsay; Nicos A Nicola; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.